Brief: Syros Pharmaceuticals Q4 EPS USD -2.18
27/03/2024 11:30
Mar 27 (Reuters) - Syros Pharmaceuticals Q4 income from operations USD -27.141 million. * Q4 net income USD -64.384 million * Q4 revenue USD 387 thousand vs. IBES estimate USD 2 million * Q4 operating expenses USD 27.528 million
Recent news on Syros Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Syros falls after blood cancer drug fails in late-stage trial